ntiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)

Jittamala P., Boyd S., Schilling WHK., Watson JA., Ngamprasertchai T., Siripoon T., Luvira V., Batty EM., Wongnak P., Esper LM., Almeida PJ., Cruz C., Ascencao FR., Aguiar RS., Ghanchi NK., Callery JJ., Singh S., Kruabkontho V., Ngernseng T., Tubprasert J., Madmanee W., Suwannasin K., Promsongsil A., Hanboonkunupakarn B., Poovorawan K., Potaporn M., Srisubat A., Loharjun B., Taylor WRJ., Qamar F., Kazi AM., Beg MA., Chommanam D., Vidhamaly S., Chotivanich K., Imwong M., Pukrittayakamee S., Dondorp AM., Day NPJ., Teixeira MM., Piyaphanee W., Phumratanaprapin W., White NJ.

DOI

10.1016/j.eclinm.2024.103036

Type

Journal article

Publisher

Elsevier BV

Publication Date

2025-02-01T00:00:00+00:00

Volume

80

Pages

103036 - 103036

Total pages

0

Permalink More information Close